Latest Breaking News On - Office of orphan product development - Page 6 : comparemela.com

Jazz Pharmaceuticals plc: Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

Treatment with Xywav resulted in clinically meaningful improvement in idiopathic hypersomnia symptoms, including excessive daytime sleepiness, sleep inertia and prolonged sleep duration with

U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity.

Jazz Pharmaceuticals plc: U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

ODE for IH for adults follows June 2021 grant of ODE for treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy DUBLIN, Jan. 3, 2022 /PRNewswire/

Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults